ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Meredith Cook also recently made the following trade(s):
- On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.54, for a total value of $23,816.00.
- On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00.
ANI Pharmaceuticals Stock Performance
ANIP stock traded down $0.13 during midday trading on Tuesday, reaching $64.22. The company had a trading volume of 233,027 shares, compared to its average volume of 238,092. The firm has a market capitalization of $1.40 billion, a PE ratio of -116.76 and a beta of 0.63. The stock has a 50 day moving average price of $58.59 and a 200 day moving average price of $58.07. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.
Analyst Upgrades and Downgrades
ANIP has been the subject of a number of analyst reports. Guggenheim increased their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $80.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $79.75.
Check Out Our Latest Research Report on ANI Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in ANI Pharmaceuticals by 41.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company's stock worth $2,648,000 after buying an additional 13,948 shares during the period. Stonepine Capital Management LLC bought a new position in shares of ANI Pharmaceuticals during the fourth quarter worth about $1,128,000. Rafferty Asset Management LLC bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $200,000. ProShare Advisors LLC boosted its stake in ANI Pharmaceuticals by 29.0% during the 4th quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company's stock valued at $361,000 after purchasing an additional 1,469 shares during the period. Finally, Nomura Holdings Inc. grew its position in ANI Pharmaceuticals by 1.5% in the 4th quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company's stock worth $11,823,000 after purchasing an additional 3,255 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Recommended Stories
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
